Building An Unconventional Biotech

In the summer of 2015, the biotech startup Morphic Therapeutic consisted of a handful of scientists looking for affordable lab space in Boston. Backed by the renowned researcher and investor, Tim Springer, the small company had an audacious mission: to unlock the secrets of a class of cell adhesion molecules known as integrins. From shopping at secondhand supply warehouses to striking deals with some of the biggest names in pharma, this is the story of how Morphic Therapeutic came to be-and where the company is heading.